The Iceland based healthcare investor, Aztiq (“Aztiq”), founded by Alvogen’s Chairman and CEO, Róbert Wessman and Innobic Asia (“Innobic”), a wholly-owned Life Science arm of PTT Public Company Limited (“PTT”, SET ticker: PTT), Thailand’s largest publicly traded conglomerate, have signed a definitive agreement to acquire a 100% stake in Alvogen Emerging Market Holdings Limited (“AEMH”) from Alvogen Lux Holdings Sarl (“Alvogen”). Key shareholders in Alvogen include CVC Capital Partners (“CVC”) and Temasek Holdings of Singapore (“Temasek”), as well as Aztiq. The total transaction value is estimated to be approximately US$475 million, and the deal is expected to close during the first quarter 2022.
With this transaction the consortium becomes the leading shareholder in the global oncology pharmaceutical company Lotus Pharmaceuticals (“Lotus”, TWSE ticker: 1795), and the owner of 100% shares in Alvogen Malta (Out-Licensing) Holding Ltd., shareholder of the fast-growing global business to business (B2B) pharmaceutical company Adalvo.
Alvogen Lux Holdings Sarl will remain a leading shareholder in the generics pharmaceutical company Alvogen US, including specialty pharma company Almatica, as well as being the second largest shareholder in global biosimilar company Alvotech.
Róbert Wessman, Chairman and CEO of Alvogen and Founder of Aztiq, will continue to serve as Chairman of the board of Lotus and Adalvo.
Alvogen acquired a majority stake in Lotus in 2014 and together with its shareholders, Lotus has evolved into a next generation pharmaceuticals company focused on global oncology with direct market access in more than 10 countries in Asia and global reach of its portfolio to over 130 markets.
Alvogen has further developed Adalvo in 2018 from an in-house B2B platform into a separate business unit focusing on global markets. In a short period of time, Adalvo has achieved a remarkable growth with over 500 transactions and a world class portfolio of 60 differentiated medicines and is currently one of the fastest growing B2B pharmaceutical company globally, serving its partners and patients in over 100 markets around the world.
In April of 2021, Innobic invested approximately US$50 million into Lotus by acquiring newly-issued shares via a private placement. Both parties, Lotus and Innobic, are committed to further collaboration with the aim of expanding access to high quality medicines. Further participation by Innobic, through its investment in AEMH, demonstrates both a strong belief in the Lotus strategy as well as a commitment to drive opportunities in South East Asian pharmaceutical markets including Thailand, Vietnam, Philippines, Malaysia and other ASEAN countries.
For full release please visit: www.alvogen.com